RMC No. 57-2022 updates the VAT-exempt list under the CREATE Act to include medicines for hypertension, diabetes, and COVID-19, requiring businesses to adjust invoicing and VAT reporting.

Businesses and healthcare providers must immediately account for the updated VAT-exempt status of certain medicines for hypertension, diabetes, and COVID-19, effective from April 27, 2022. Failure to recognize this update could result in incorrect VAT reporting and potential compliance issues.

What Changed

RMC No. 57-2022 officially publishes the February 2, 2022 letter from the Food and Drug Administration (FDA) endorsing an update to the List of VAT-Exempt Medicines under Republic Act No. 11534, also known as the CREATE Act. The updated list now includes specific medicines used in the treatment of hypertension, diabetes, and COVID-19. This means that transactions involving these medicines are not subject to the 12% VAT, impacting both suppliers and healthcare service providers.

Who is Affected

Manufacturers, importers, distributors, pharmacists, hospitals, clinics, and other healthcare facilities selling or dispensing these medicines must adjust their accounting and billing systems. Accountants and CFOs need to ensure that invoices and tax returns reflect the VAT exemption, while tax practitioners must verify that the transactions qualify under the updated list to avoid potential disputes with the BIR.

Key Compliance Requirements and Deadlines

All entities handling the listed medicines must:

1. Update accounting and invoicing systems to exclude VAT on these specific medicines effective April 27, 2022.

2. Maintain documentation supporting the VAT-exempt status of these medicines, including purchase invoices, FDA certifications, and internal product lists aligned with the RMC.

3. Reflect the VAT-exempt status accurately in periodic VAT returns filed with the BIR to avoid misstatements.

No further deadlines are explicitly stated in the RMC, but businesses should implement the updates immediately to ensure compliance for all ongoing and future sales.

Penalties for Non-Compliance

Failure to properly apply VAT exemption may result in assessments for unpaid VAT, penalties, and interest under the National Internal Revenue Code. The BIR may also require adjustments or additional documentation during audits, increasing administrative burden and potential exposure.

Practical Steps for Businesses

Accounting and tax departments should review their medicine inventory to identify those newly covered under the VAT-exempt list. Invoices and point-of-sale systems must be updated to reflect the exemption. Training for staff responsible for billing and compliance is advisable. Regular audits of VAT reporting related to these medicines can prevent misstatements and ensure smooth compliance with BIR regulations.

For businesses looking for expert guidance on implementing the VAT exemption for these medicines and maintaining compliance with RMC No. 57-2022, Ablola, Saribong & Gueco provides specialized tax advisory and compliance services. Visit MakatiLawFirm.com to connect with our team of experts.

Leave a Comment

Your email address will not be published. Required fields are marked *